Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. uri icon

authors

  • Mayer-Hamblett, Nicole
  • Taylor-Cousar, Jennifer L
  • Goss, Christopher H
  • Retsch-Bogart, George
  • Clancy, John Paul
  • Genatossio, Alan
  • O'Sullivan, Brian P
  • Berlinski, Ariel
  • Millard, Susan L
  • Omlor, Gregory
  • Wyatt, Colby A
  • Ratjen, Felix
  • Moffett, Kathryn
  • Nichols, David P
  • Gifford, Alex H
  • Russell, Renee
  • Donaldson, Scott H
  • Riekert, Kristin A
  • Sawicki, Gregory S
  • Odem-Davis, Katherine
  • Young, Julia K
  • Rosenbluth, Daniel

publication date

  • January 1, 2022